Viking Therapeutics, Inc.
VKTX
$23.94
$0.341.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -43.94% | -10.68% | -15.73% | -40.06% | -25.80% |
| Total Depreciation and Amortization | 48.65% | 19.18% | 2.74% | 2.78% | 2.78% |
| Total Amortization of Deferred Charges | -7.69% | 1,100.00% | -43.75% | 0.00% | 225.00% |
| Total Other Non-Cash Items | 18.59% | 189.67% | -37.82% | 61.94% | -33.04% |
| Change in Net Operating Assets | -55.16% | -170.93% | -259.62% | 289.80% | -15.48% |
| Cash from Operations | -76.76% | -11.72% | -149.35% | 75.11% | -61.45% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -81.57% | 306.65% | 38.35% | -21,018.65% | 392.19% |
| Cash from Investing | -81.57% | 306.65% | 38.35% | -21,018.65% | 392.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 431.91% | -- | -98.93% | 10,820.61% | -98.41% |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | -2,356.30% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 431.91% | 3,508.11% | -98.91% | 14,384.63% | -98.25% |
| Foreign Exchange rate Adjustments | -248.00% | 57.35% | 200.00% | -433.33% | -64.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -229.13% | 119.89% | -396.47% | 866.63% | 153.75% |